Pipeline

The Company's emerging pipeline of highly differentiated biased ligand drugs is focused on therapy areas that have significant unmet medical needs such as cardiovascular disease, CNS (pain), inflammation and oncology supportive care.

Trevena expects to enter Phase I clinical trials with the first ever biased ligand drug candidate to treat patients with acute heart failure in the first half of 2010.

Trevena’s second program is a small molecule G-protein biased ligand in pain, currently in lead optimization. Trevena also has a number of early-stage discovery projects.